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Abstract
Background: The Chronic Disease Care System (CDCS) has been implemented in Korea to encourage treatment
continuity in chronic disease patients. This study investigated the effect of the introduction of the CDCS on health
care costs and continuity of care in individuals with type 2 diabetes mellitus (T2DM).
Methods: The National Health Insurance data from August, 2010 to March, 2012 (pre-policy) and from May, 2012 to
December, 2013 (post-policy) were used. Introduction of the CDCS was defined as the intervention. The intervention
group consisted of T2DM patients participating in the program and the control group patients not participating in the
program. The Difference-in-Differences (DID) method was used to estimate the differences in total health care costs for
outpatient services and continuity of care between the intervention and the control group before and after the
intervention period.
Results: Implementation of the CDCS was associated with decreased health care costs (β = − 46,877 Korean
Won, P < 0.0001) and improved continuity of care (β = 0.0536, P < 0.0001) in the intervention group with
adjustment for covariates.
Conclusion: Findings confirm an association between the adoption of the CDCS and reduced health care
costs and improved continuity of care. The results reveal the potential benefits of reinforcing effective chronic
disease management strategies in reducing health care costs and improving treatment continuity.
Keywords: Chronic disease care system, Primary health care, Health care costs, Continuity of care, Treatment
continuity, Chronic disease
Background
Diabetes mellitus is a global public health problem, with
the number of affected individuals expected to rise from
360 million in 2011 to 550 million in 2030 [1]. The
prevalence of diabetes has also increased from around
nine to 11% between 2011 and 2013 in South Korea,
which is alarming because diabetes and its related com-
plications often increase the burden individuals and
health care systems experience in terms of health
outcomes and costs [2, 3]. In fact, previous studies have
reported that diabetes act to decrease the health-related
quality of life (HRQoL) of affected individuals [4]. Fur-
thermore, diabetes and its related complications are a
leading cause of morbidity and mortality in Korea [5].
Specifically, the prevalence type 2 diabetes mellitus
(T2DM) has been increasing noticeably at a rate of 7.9%
among Korean adults [6, 7]. As diabetes is chronic in
nature and can lead to severe complications, including car-
diovascular disease (CVD), retinopathy, nephropathy, neur-
opathy, peripheral-vascular disease, and cerebrovascular
disease, the quality of diabetes treatment is an important
issue to address [8]. At the same time, diabetes is also
known to cause around 250 million United States dollars
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(USD) aggregate annual direct costs [9, 10]. Moreover, pa-
tients who develop diabetes related complications are
known to require higher levels of medical expenditure [9].
Considering the importance of providing proper dis-
ease management to enhance treatment quality and con-
tain costs, the government of Korea introduced the
Chronic Disease Care System (CDCS) program in 2012
[11]. The CDCS program aims to enhance care coordin-
ation by encouraging patients with T2DM or hyperten-
sion to designate a primary care clinic of their choice for
continued care [12]. By voluntarily participating in the
CDCS program, T2DM patients choose a preferred pri-
mary clinic and agree to consistently receive care from
the selected institution. Participation assures a reduction
of out-of-pocket costs for outpatient services from the
regular 30 to 20% of total costs, along with the provision
of health support services, such as consultation and edu-
cation. Health care providers are separately provided
with incentives after assessment by the Health Insurance
Review and Assessment Service (HIRA).
The government expects that the CDCS program will
improve treatment quality by improving continuity of
care, in addition to equipping patients with better dis-
ease self-management skills. Implementation of the
CDCS program has been expected to enhance continuity
of care, which is significant because Korea lacks a per-
sonalized general practitioner (GP) based primary care
system [13]. Additionally, because continuity of care has
been associated with indicators of patient prognoses, in-
cluding the development of complications, mortality,
emergency room visits, and hospital admissions, pro-
moting care coordination is also essential in maintaining
health care costs [14]. Therefore, the purpose of this
study was to estimate the effect of the CDCS implemen-
tation on health care costs and continuity of care in
patients with T2DM.
Methods
Study population
This study used the Korea National Health Insurance
(NHI) cohort data. In Korea, all individuals are covered
by either the NHI or Medical Aid and the NHI is known
to cover around 98% of the total population. The NHI
cohort data were constructed based on 1,025,340 nation-
ally representative random samples of the entire 2002
population. The sample population equals around 2.2%
of the 46,605,433 residents recorded by the Korean Na-
tional Health Insurance Service (KNHIS). Data were col-
lected using a systematic sampling method and include
all filed medical claims between 2002 and 2013.
Data from August, 2010 to March, 2012 (pre-policy)
and from May, 2012 to December, 2013 (post-policy)
were used because the CDCS, defined as the interven-
tion, was implemented on April, 2012. Individuals
diagnosed primarily of T2DM (International Classifica-
tion of Diseases version 10 [ICD-10] E11) were included.
The control group included T2DM diagnosed individ-
uals not participating in the CDCS program and the
intervention group patients who voluntarily opted to
participate in the CDCS program.
The study population comprised of adults aged be-
tween 20 and 65 years. Older aged individuals were ex-
cluded as they have different levels of disease severity
and exhibit unalike treatment patterns. Individuals aged
65 or above are also subject to lower levels of cost shar-
ing for outpatient services that cost up to 15,000 Korean
Won [KRW, (1 USD = 1128 KRW)]. Individuals with less
than 3 outpatient physician visits were also omitted to
ensure consistency in measuring continuity of care. Add-
itionally, Medical Aid beneficiaries were not included as
they are subject to different levels of copayment and
often have different health care utilization patterns. The
final study population consisted of 3388 individuals in
the intervention and 14,191 individuals in the control
group during the pre-implementation period and 3184
individuals in the intervention and 13,036 individuals in
the control group during the post-implementation
period.
Variables
The dependent variables were total health care costs for
covered outpatient services and continuity of care. Continu-
ity of care was measured using the usual provider of care
(UPC) index, defined as the number of outpatient visits to
the most frequently seen physician divided by the total
number of outpatient visits [15]. The UPC index concen-
trates on the number of physicians seen by a patient and
the visit ratio of the most frequently seen physician to all
visited physicians. All values range between zero and one.
Demographic, socioeconomic, and health related vari-
ables were incorporated as covariates. The included vari-
ables were age at diagnosis (20 to 29, 30 to 39, 40 to 49,
50 to 59, or 60 to 64), sex (male or female), income (low,
middle, or high), region (Seoul, metropolitan, or rural),
NHI type (occupational or regional), comorbidities mea-
sured using the Charlson Comorbidity Index (0, 1, 2, 3+),
disability status (no or yes), medication prescription status
(none, insulin only, hypoglycemic agent only, or insulin
and hypoglycemic agent), and diabetes related complica-
tion status (no or yes). Hypoglycemic agents included sul-
fonylureas, metformin, alpha glucosidase inhibitors, and
thiazolidinedione. Complications refer to retinopathy, ne-
phropathy, neuropathy, peripheral vascular disease, cere-
brovascular disease, and cardiovascular disease (CVD) [8].
Statistical analysis
Quantitative data at baseline and follow up were examined
using the chi-square test. The Difference-in-Differences
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(DID) method was utilized to estimate differences in total
health care costs and continuity of care between the inter-
vention and the control group before and after the inter-
vention period. The DID method is a quasi-experimental
method that focuses on capturing effects related to a cer-
tain event through time between the control and the inter-
vention group [16]. The DID specification of this study
were yi¼β0þβ1 ∙timeiþγ ∙groupiþδ∙groupi ∙timeiþεi . In this regression
analysis, β0 measures the mean outcome of the con-
trol group at baseline, β0+β1 the mean outcome of
the control group at follow up, γ the difference be-
tween the control and the intervention group at base-
line, β0+ γ the mean outcome of the intervention
group at baseline, β0+β1 + γ + δ the mean outcome of
the intervention group at follow up, δ the DID of the
intervention, and εithe random error.
Both adjusted and unadjusted analysis were carried
out. All calculated P values were two sided, considered
significant at < 0.05. Analysis was performed using the
SAS software, version 9.4 (SAS Institute, Cary, NC,
USA).
Results
Table 1 shows the general characteristics of the study
participants at baseline and follow-up. At the
pre-implementation period, a total of 3388 individuals were
included in the intervention group and 14,191 individuals
in the control group. Similarly, at post-implementation
period, 3184 individuals were included in the intervention
group and 13,036 individuals in the control group. Charac-
teristics were generally similar between the control and the
intervention group, although the control group consisted of
a higher percentage of males and a lower percentage of low
income individuals. The control group also had a higher
proportion of individuals with disability and those diag-
nosed with diabetes related complications.
Table 2 presents the results of the DID model. The
effect of the intervention on health care cost was shown
through the coefficient of the interaction term
post-policy*intervention. Model 1 reveals the effect of
the intervention without adjustment for covariates and
model 2 with adjustment for covariates. In terms of
health care costs, the coefficient of model 1 (β = −
47,523 KRW, P < 0.0001) and model 2 (β = − 46,877
KRW, P < 0.0001) were statistically significant. This
implies a positive relationship between implementation
of the CDCS and reduced health care costs for covered
outpatient services. Likewise, regarding continuity of
care, the coefficient of the interaction term
post-policy*intervention was significant in model 1 (β =
0.0537, P < 0.0001) and model 2 (β = 0.0536, P < 0.0001).
The results infer that the adoption of the CDCS was as-
sociated with improved continuity of care.
Discussion
This study investigated the impact of the CDCS on
health care costs and continuity of care in Korean adults
diagnosed with T2DM. The findings reveal that imple-
mentation of the CDCS was associated with reduced ex-
penditures for covered outpatient services and modest
improvements in continuity of care. The presented re-
sults are in accordance with the expectations of the gov-
ernment, which aimed to incentivize treatment
continuity because enhanced coordination has been
known to improve quality of care and patient outcomes,
which in turn acts to impact the level of health care ex-
penditures [17].
Improvements in continuity of care found in this study
are noteworthy because establishing an effective
long-term care management plan and improving patient
adherence is important in managing chronic diseases. In
fact, because chronic diseases cannot be fully cured, pa-
tients need to be constantly monitored and well
equipped with self-management skills [18]. By improving
continuity of care, which familiarizes physicians to pa-
tient history, better monitoring of glycemic levels and
management of disease related complications can be
achieved [19]. At the same time, generating
physician-patient trust has also been demonstrated to
advance treatment adherence [20]. Correspondingly, pre-
vious studies have shown that enhanced treatment con-
tinuity can improve patient satisfaction and quality of
life, reduce emergency department visits and hospitaliza-
tions related to complications, and improve patient out-
comes [19, 21, 22]. However, because the primary care
system of Korea generally does not function to promote
continuity or coordination, many patients are often
poorly educated on diabetes-related self-management
skills [23]. In fact, the percentage of patients successfully
carrying out glucose management have decreased from
around 34 to 23% between 2005 and 2014, and almost
half of male diabetes patients are reported to smoke
[24]. Under such circumstances, implementation of the
CDCS may have aided to improve treatment continuity
in T2DM patients.
According to the study results, implementation of the
CDCS was also related to decreased health care costs for
covered outpatient services. Occurrences of T2DM and
its related complications have consistently been noted as
factors that escalate health care costs [25, 26]. In Korea,
macro and micro vascular complications in T2DM pa-
tients have specifically been reported to cause higher
levels of annual direct medical costs, with expenditures
increasing with the number of complications [9]. By in-
centivizing diabetes patients to utilize primary clinics in-
stead of secondary or tertiary hospitals, the CDCS may
have acted to decrease diabetes related health care ex-
penditures by promoting a more effective use of health
Kim et al. BMC Health Services Research          (2018) 18:991 Page 3 of 7
care resources at the national level. Moreover, the CDCS
could have led to reductions in health care costs by in-
ducing treatment continuity considering that better con-
tinuity has been previously associated with decreases in
health care utilization and expenses [19]. In fact,
previous findings have conveyed that poor treatment
continuity can escalate risks for diabetic complications
and induce heavier health care utilization, which natur-
ally necessitates increases in medical expenditure [19].
Frequent doctor switching may also lead to interruptions
Table 1 Characteristics of the intervention and the control group before and after policy implementation
Pre-implementation period Post-implementation period
Control group Intervention group Control group Intervention group
Total 14,191 (80.7) 3388 (19.3) 13,036 (80.4) 3184 (19.6)
Age
20–29 144 (1.0) 26 (0.8) 94 (0.7) 15 (0.5)
30–39 928 (6.5) 193 (5.7) 643 (4.9) 112 (3.5)
40–49 3699 (26.1) 883 (26.1) 2856 (21.9) 651 (20.4)
50–59 7183 (50.6) 1780 (52.5) 6238 (47.9) 1580 (49.6)
60–64 2237 (15.8) 506 (14.9) 3205 (24.6) 826 (25.9)
Sex
Male 8911 (62.8) 2063 (60.9) 8252 (63.3) 1935 (60.8)
Female 5280 (37.2) 1325 (39.1) 4784 (36.7) 1249 (39.2)
Income
Low 4241 (29.9) 1097 (32.4) 3536 (27.1) 976 (30.7)
Middle 4033 (28.4) 1055 (31.1) 3544 (27.2) 967 (30.4)
High 5219 (36.8) 1230 (36.3) 5208 (40.0) 1239 (38.9)
NHI type
Occupational 8122 (57.2) 2016 (59.5) 7725 (59.3) 1985 (62.3)
Regional 5371 (37.8) 1366 (40.3) 4563 (35.0) 1197 (37.6)
Region
Seoul 2670 (18.8) 562 (16.6) 2402 (18.4) 521 (16.4)
Metropolitan 3782 (26.7) 1006 (29.7) 3423 (26.3) 963 (30.2)
Rural 7739 (54.5) 1820 (53.7) 7211 (55.3) 1700 (53.4)
Charlson Comorbidity Index
0 711.0 (5.0) 149 (4.4) 568.0 (4.4) 115.0 (3.6)
1 6765 (47.7) 1657 (48.9) 6187 (47.5) 1604 (50.4)
2 2573 (18.1) 664 (19.6) 2363 (18.1) 611 (19.2)
3+ 4142 (29.2) 918 (27.1) 3918.0 (30.1) 854.0 (26.8)
Disability
No 12,832 (90.4) 3139 (92.7) 11,684 (89.6) 2940 (92.3)
Yes 1359 (9.6) 249 (7.3) 1352 (10.4) 244 (7.7)
Medication
None 546 (3.8) 39 (1.2) 476 (3.7) 30 (0.9)
Insulin only 183 (1.3) 45 (1.3) 163 (1.3) 36 (1.1)
Hypoglycemic agent only 12,530 (88.3) 3147 (92.9) 11,544 (88.6) 2964 (93.1)
Insulin & hypoglycemic agent 932 (6.6) 157 (4.6) 853 (6.5) 154 (4.8)
Complication
No 8258 (58.2) 2050 (60.5) 7626 (58.5) 1966 (61.7)
Yes 5933 (41.8) 1338 (39.5) 5410 (41.5) 1218 (38.3)
*NHI=National Health Insurance
Hypoglycemic agents include sulfonylureas, metformin, alpha glucosidase inhibitors, and thiazolidinedione
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Table 2 Differential changes in spending and continuity of care between the intervention and the control group
Total cost Continuity of Care
Model 1 Model 2 Model 1 Model 2
β SE p-value β SE p-value β SE p-value β SE p-value
Pre-policy Ref Ref Ref Ref
Post-policy −15,419 3639 <.0001 −12,789 3665 0.0005 0.0055 0.0016 0.0009 0.0050 0.0017 0.0025
Control group Ref Ref Ref Ref
Intervention group − 9589 3078 0.0018 − 5895 3014 0.0505 0.0093 0.0016 <.0001 0.0093 0.0016 <.0001
Post-policy*Intervention group −47,523 4700 <.0001 −46,877 4724 <.0001 0.0537 0.0025 <.0001 0.0536 0.0026 <.0001
Age
20–29 Ref Ref
30–39 −63,369 31,611 0.045 0.0070 0.0123 0.5706
40–49 −70,130 31,402 0.0255 0.0118 0.0119 0.3201
50–59 −69,671 31,320 0.0261 0.0130 0.0118 0.2729
60–64 −91,574 31,416 0.0036 0.0139 0.0119 0.2446
Sex
Male Ref Ref
Female 28,995 5011 <.0001 −0.0037 0.0019 0.0481
Income
Low Ref Ref
Middle 6009 5507 0.2751 0.0003 0.0023 0.9045
High 7620 4928 0.122 0.0085 0.0021 <.0001
NHI type
Occupational Ref Ref
Regional 6311 4486 0.1594 −0.0080 0.0018 <.0001
Region
Seoul Ref Ref
Metropolitan 5500 6125 0.3693 −0.0052 0.0027 0.0525
Rural 6885 5678 0.2253 −0.0049 0.0024 0.0394
Charlson Comorbidity Index
0 Ref Ref
1 −13,878 6915 0.0448 −0.0201 0.0036 <.0001
2 − 4345 8483 0.6086 −0.0196 0.0040 <.0001
3+ 10,013 7837 0.2013 −0.0420 0.0039 <.0001
Disability
No Ref Ref
Yes 35,482 10,247 0.0005 −0.0101 0.0035 0.0035
Medication
None Ref Ref
Insulin only −74,185 39,588 0.0609 −0.0375 0.0097 0.0001
Hypoglycemic agent only − 134,483 21,686 <.0001 −0.0320 0.0040 <.0001
Insulin & hypoglycemic agent 3280 27,210 0.9041 −0.0662 0.0057 <.0001
Complication
No Ref Ref
Yes 35,446 4322 <.0001 −0.0042 0.0019 0.0304
*NHI=National Health Insurance
Hypoglycemic agents include sulfonylureas, metformin, alpha glucosidase inhibitors, and thiazolidinedione
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in medicine prescription, negatively interfering with patient
monitoring and cultivation of self-management skills [3].
As provision of higher quality care is important in man-
aging T2DM patients, this study offers insight by revealing
the potential benefits of employing policies that promote a
more effective use of health care resources [27].
The findings of this study should be interpreted while
accounting for the following limitations. First, not all pri-
mary clinics participated in the CDCS program. The pro-
gram participation rate was around 63% in 2014. Hence,
some individuals may have faced difficulties in accessing
primary clinics that offer the CDCS program. Second, re-
ductions in total health care costs may have been partially
affected by the policy implemented in 2012 that reduced
total pharmaceutical costs at an average of around 14%.
However, this study did adjust for pharmaceutical pre-
scription status to partially overcome this limitation.
Third, health care costs measured in this study only
accounted for services reimbursed by the KNHIS. As
Korea uses both a positive and a negative list system to de-
termine service reimbursement status, a grey zone of
non-covered services that fully depend on patient out of
pocket costs exist. As this study only considered costs for
covered services due to data limitation, the results cannot
be seen as a reflection of total T2DM related costs.
Fourth, medical illnesses were identified and categorized
solely based on the ICD-10 code. Thus, there may have
been some inaccuracies in diagnosis coding. Fifth, phar-
maceuticals were classified only based on prescription sta-
tus, which does not necessarily imply consumption or
medical adherence. Last, this study may not have been
able to adjust for all potential risk factors, which implies
that there may be a possibility of residual confounding.
However, despite the limitations stated above, this study is
noteworthy as it provides evidence on how implementa-
tion of the CDCS affected health care costs and continuity
of care in T2DM diagnosed patients.
Conclusion
This study analyzed the effect of the implementation of
the CDCS on health care costs for outpatient services and
continuity of care in T2DM patients. The results confirm
an association between the adoption of the CDCS and re-
duced health care costs and improved continuity of care.
The discoveries offer insight by signifying the potential
benefits of employing effective chronic disease manage-
ment strategies in reducing health care costs and improv-
ing treatment continuity in T2DM patients.
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